StockNews.com Issues 'Sell' Rating for Cyclacel Amid Financial Challenges StockNews.com has initiated coverage on Cyclacel Pharmaceuticals with a 'sell' rating. The stock, trading at $0.30, has faced significant losses, with market capitalization dropping to $1.87 million. Insider activity, including a large stock sale by the former CEO, has further highlighted the company’s ongoing financial difficulties.678